O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

Covid -19.pptx

Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Próximos SlideShares
Benign Breast Diseases.pptx
Benign Breast Diseases.pptx
Carregando em…3
×

Confira estes a seguir

1 de 53 Anúncio
Anúncio

Mais Conteúdo rRelacionado

Mais de Pradeep Pande (20)

Mais recentes (20)

Anúncio

Covid -19.pptx

  1. 1. Tips on using my ppt. 1. You can freely download, edit, modify and put your name etc. 2. Don’t be concerned about number of slides. Half the slides are blanks except for the title. 3. First show the blank slides (eg. Aetiology ) > Ask students what they already know about ethology of today's topic. > Then show next slide which enumerates aetiologies. 4. At the end rerun the show – show blank> ask questions > show next slide. 5. This will be an ACTIVE LEARNING SESSION x three revisions. 6. Good for self study also. 7. See notes for bibliography.
  2. 2. Learning Objectives
  3. 3. Learning Objectives 1. Introduction & History 2. Relevant Anatomy, Physiology 3. Aetiology 4. Pathophysiology 5. Pathology 6. Classification 7. Clinical Features 8. Investigations 9. Management 10. Prevention 11. Guidelines 12. Take home messages
  4. 4. Introduction & History. •
  5. 5. Introduction & History. • Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2; formerly called 2019-nCoV), • First identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.
  6. 6. Introduction & History. • It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency. [2, 3] On March 11, 2020, the WHO declared COVID-19 a global pandemic,
  7. 7. Aetiology
  8. 8. Aetiology • Idiopathic • Congenital/ Genetic • Nutritional Deficiency/excess • Traumatic • Infections /Infestation • Autoimmune • Neoplastic (Benign/Malignant) • Degenerative / lifestyle • Iatrogenic • Psychosomatic • Poisoning/ Toxins/ Drug induced
  9. 9. Aetiology • Idiopathic • Congenital/Genetic • Traumatic • Infections /Infestation • Autoimmune • Neoplastic (Benign/Malignant) • Degenerative • Iatrogenic
  10. 10. Aetiology • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV).
  11. 11. Aetiology of Aetiology •
  12. 12. Aetiology of Aetiology • Idiopathic • Congenital/ Genetic • Nutritional Deficiency/excess • Traumatic • Infections /Infestation • Autoimmune • Neoplastic (Benign/Malignant) • Degenerative / lifestyle • Iatrogenic • Psychosomatic • Poisoning/ Toxins/ Drug induced
  13. 13. Classification
  14. 14. Classification • Asymptomatic • Mild 81% • Severe 14% • Critical 5% – ARDS • Fatal 2.3%
  15. 15. Clinical Features •
  16. 16. Clinical Features • Demography • Symptoms • Signs • Prognosis • Complications
  17. 17. Demography
  18. 18. Demography • Incidence & Prevalence • Geographical distribution. • Race • Age • Sex • Socioeconomic status • Temporal behaviour
  19. 19. Demography • Incidence & Prevalence-
  20. 20. Demography • Geographical distribution.
  21. 21. Demography • Race.
  22. 22. Demography • Age
  23. 23. Demography • Sex
  24. 24. Demography • Socioeconomic status
  25. 25. Demography • Temporal behaviour
  26. 26. Symptoms
  27. 27. Symptoms • Presentations of COVID-19 have ranged from asymptomatic/mild symptoms to severe illness and mortality. • Mean incubation period to be 5.1 days 2 days to 2 weeks.
  28. 28. Symptoms Common • Fever • Cough • Myalgia • Fatigue Less-common • Headache • Sputum production • Diarrhea • Malaise • Shortness of breath/dyspnea • Respiratory distress
  29. 29. Symptoms • The most common serious manifestation of COVID-19 appears to be pneumonia. • A complete or partial loss of the sense of smell (anosmia) has been reported as a potential history finding . Its clinical importance is questionable
  30. 30. Signs
  31. 31. Signs • General Examination • Systemic Examination • Local Examination
  32. 32. Signs • General Examination
  33. 33. Signs • Systemic Examination
  34. 34. Signs • Local Examination
  35. 35. Prognosis
  36. 36. Prognosis • Morbidity • Mortality rate • 5 year survival in Malignancy
  37. 37. Investigations
  38. 38. Investigations • Laboratory Studies – Routine – Special • Imaging Studies • Tissue diagnosis – Cytology • FNAC – Histology – Germ line Testing and Molecular Analysis • Diagnostic Laparotomy.
  39. 39. Investigations • Laboratory Studies – Routine – Special • Imaging Studies • Tissue diagnosis – Cytology • FNAC – Histology
  40. 40. Investigations in Malignancy •
  41. 41. Investigations in Malignancy • For diagnosis • For staging • For Screening • For Monitoring
  42. 42. Diagnostic Studies
  43. 43. Diagnostic Studies Imaging Studies • X-Ray • USG • CT • Angiography • MRI • Endoscopy • Nuclear scan
  44. 44. Management
  45. 45. Management • Early Oxygen support • No Steroids • Conservative fuid management. • Monitoring • Co- Morbidities. • Early communication • Early mechanical ventilation • No Lopinavir • Hydroxychloroquine • Azithromycin • Tocilizumab • Empiric Antibiotics
  46. 46. Mechanical Ventilation • Low tidal volume 4-8ml/Kg • Low plateau pressure <30cm of water • High PEEP • Permissive hypercapnoea • Deep sedation • Prone • Target Spo2 90%
  47. 47. Prevention
  48. 48. Prevention • Screening • Risk reduction
  49. 49. Mythbusters Myths Facts
  50. 50. Guidelines
  51. 51. Get this ppt in mobile 1. Download Microsoft PowerPoint from play store. 2. Open Google assistant 3. Open Google lens. 4. Scan qr code from next slide.
  52. 52. Get this ppt in mobile
  53. 53. Get my ppt collection • https://www.slideshare.net/drpradeeppande/ edit_my_uploads • https://www.dropbox.com/sh/x600md3cvj8 5woy/AACVMHuQtvHvl_K8ehc3ltkEa?dl =0 • https://www.facebook.com/doctorpradeeppa nde/?ref=pages_you_manage

Notas do Editor

  • drpradeeppande@gmail.com
    7697305442

×